Drug Security Forum

Antibiotics and Safety: How Can Antibiotics Remain Effective?

14 Jun , 12:15–13:45
‘Ensuring Drug Security’ Russian Pharmaceutical Forum
Pavilion G, conference hall G4

Antibiotics were invented 95 years ago. World medicine has developed a unique opportunity to save lives and defeat deadly diseases in whole or in part. Today, however, antibiotics have become a cause for alarming debate in the medical expert community. Unrestricted use of antibiotics is becoming a global problem and could lead to a fatal reduction in their effectiveness against infectious diseases. To date, around 700,000 people worldwide die each year from infections caused by antibiotic-resistant pathogens. According to some experts, antibiotic resistance could cause 10 million deaths a year by 2050. Compounding the problem is the fact that the global drug market is experiencing a shortage of innovative new drugs to fight the most dangerous and resistant pathogens. What changes to the marketing and prescribing of antibiotics can reverse their overuse? How can control of the circulation of antibiotics in the pharmaceutical market be strengthened, while their production, distribution, and use more carefully regulated? Can epidemiological surveillance limit the uncontrolled use of antibiotics? Will the world be able to withstand the spread of antimicrobial resistance and how will it deal with future infectious diseases?

Olga Kobyakova, Director, Federal Research Institute for Health Organization and Informatics of Ministry of Health of the Russian Federation

Renad Alyautdin, Head of the Department for Expertise of the Safety of Medicines, Federal State Budgetary Institution "Scientific Center for Expertise of Medicinal Products" of the Ministry of Health of Russia
Oksana Drapkina, Director, National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Roman Kozlov, Chief Freelance Specialist of the Ministry of Health of the Russian Federation for Clinical Microbiology and Antimicrobial Resistance; President, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC)
Yury Lobzin, Children’s Clinical Research Centre for Infectious Diseases, Federal Biomedical Agency
Yulia Mihaleva, Deputy Director, Russian Quality System (Roskachestvo)
Alla Samoylova, Head, Federal Service for Surveillance in Healthcare (Roszdravnadzor)